“For biotechnology companies with market cap >$10B that have 1–3 Phase 3 drug candidates with expect before 2026-04-30”
The screen covers 5 company–candidate rows — every company that passed the interpreted filter: US-listed biotechnology, April 2026 market capitalization above $10 billion (USD), and one to three Phase 3 candidates with an efficacy, topline, primary-endpoint, or detailed-result event expected or occurring by April 30, 2026. Each qualifier turned out to hold exactly one such candidate. Four events are confirmed or dated; Insmed’s remains an estimated Q1 2026 topline in the evidence found by the cutoff.
This is a catalyst screen, not investment advice. Trial starts, enrollment updates, FDA meetings, and filings were excluded.
| Company | Ticker | Market cap | Candidate | Trial | Indication | Milestone timing | Event source | Cap source |
|---|
Method: catalyst screen of publicly traded biotechnology companies, 5 company–candidate rows, one per qualifying company; market caps in USD as of the source date (April 5–30, 2026); milestone dates as stated by sources through April 30, 2026. Qualifying events are efficacy/safety results, topline readouts, primary-endpoint results, or detailed-result presentations; trial starts, enrollment or design updates, FDA meetings, and filings excluded. Source check: 5 distinct event hosts, 4 distinct market-cap hosts, no missing sources, no event URL backing more than one row. Broad but not guaranteed exhaustive: biotech classification and historical market-cap coverage differ by source. Full milestone descriptions shortened for space; see event links.